- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 562
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep
- Interventions
- Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care, Sham acupressure plus usual care
- Behavioral
- Lead sponsor
- Suzanna Zick
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- 23andMe, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Systemic Lupus Erythematosus, Lupus
- Interventions
- pravastatin, aspirin, ramipril, Vitamins: B6, B12, and folate, heart health educational program
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatic Diseases, Gout, Adherence, Medication, Lupus Erythematosus, Systemic
- Interventions
- Cue-Reward Intervention, Cue-Reward Intervention with possible intensification
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lupus
- Interventions
- Prasterone (GL701)
- Drug
- Lead sponsor
- Genelabs Technologies
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Dehydroepiandrosterone (DHEA)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
- Interventions
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Lupus Erythematosus, Systemic, SLE
- Interventions
- Physical Therapy or Relaxation Therapy
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SLE (Systemic Lupus)
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lupus Nephritis
- Interventions
- Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Covina, California • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- New York, New York • Pittsburgh, Pennsylvania • Charleston, South Carolina
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Interventions
- Skin biopsy, Blood collection, Urine collection
- Procedure
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 9
- States / cities
- La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- ultraviolet A-1 light treatment
- Procedure
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1991
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
- Conditions
- Lupus Nephritis
- Interventions
- Etanercept, Lupus Treatment- Standard of Care, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
- Conditions
- Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
- Interventions
- FIT Teens
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lupus
- Interventions
- BMS-931699, Placebo matching BMS-931699
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Fullerton, California • Long Beach, California + 22 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
- Interventions
- Dexamethasone or other corticosteroid
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2008
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Livingston, New Jersey • New York, New York
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 35
- States / cities
- Covina, California • Hemet, California • Los Angeles, California + 28 more
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Interventions
- LY2127399, Placebo every 2 weeks, Placebo every 4 weeks
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 88
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 84 more